QuantiFERON (R)-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guerin (BCG)-vaccinated country: the HUR-BIO single-center real-life results

ŞEYHOĞLU E., UYAROĞLU O. A., ERDEN A., KILIÇ L., KARADAĞ Ö., AKDOĞAN A., ...More

CLINICAL RHEUMATOLOGY, vol.40, no.5, pp.2027-2035, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1007/s10067-020-05443-3
  • Journal Name: CLINICAL RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.2027-2035
  • Keywords: Anti-TNF-alpha drugs, BCG, Latent tuberculosis, QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test, Tuberculin skin test (TST), GAMMA RELEASE ASSAYS, INFECTION, RISK, ANTAGONISTS, GUIDELINES, DIAGNOSIS
  • Hacettepe University Affiliated: Yes

Abstract

Objectives The Turkish population is vaccinated with Bacille Calmette-Guerin (BCG), and the BCG vaccination decreases the specificity of the tuberculin skin test (TST). The purpose of this study was to investigate the incidence of active tuberculosis (TBC) among rheumatic patients who were screened only with the QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test for latent TBC prior to biological treatment.